Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.43.

A number of analysts recently commented on ATNM shares. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Stephens initiated coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group decreased their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ATNM. Vanguard Group Inc. boosted its holdings in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares in the last quarter. Virtu Financial LLC increased its position in shares of Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the last quarter. Rhumbline Advisers increased its position in shares of Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after acquiring an additional 7,525 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals during the second quarter worth $142,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $2.05 on Friday. The company has a market cap of $61.06 million, a PE ratio of -1.20 and a beta of 0.20. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, sell-side analysts expect that Actinium Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.